Clinical Trials Logo

Clinical Trial Summary

This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and continuing Tislelizumab in combination with docetaxel. The primary study endpoint of this study is measured by progression-free survival (PFS). 1. Tislelizumab: The recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle. 2. Docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle. 3. Treatment cycle: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05192681
Study type Interventional
Source Fujian Cancer Hospital
Status Enrolling by invitation
Phase Phase 2
Start date October 10, 2021
Completion date October 10, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04733521 - A Phase 1/2 Study of SC-43 in Combination With Cisplatin Phase 1/Phase 2
Recruiting NCT04455984 - Multimodality Treatment Including Curative Resection of Advanced NSCLC